Table 4 Univariable and multivariable analysis of factors associated with 30-day all-cause mortality following VRE bloodstream infection
Patients who died (n = 27) | Patients who survived (n = 66) | Univariable odds ratio | 95% CI | p-value | Multivariable odds ratio | 95% CI | p-value | |
|---|---|---|---|---|---|---|---|---|
Age, median (IQR), years | 55 (44–65) | 58 (43–66) | 1.00 | 0.97–1.03 | 0.964 | |||
Male | 15 (56%) | 34 (52%) | 1.18 | 0.48–2.89 | 0.723 | |||
CDS-VRE, median (IQR) | 1.9 (1.9–3.9) | 1.9 (1.5–3.4) | 1.40 | 0.99–1.96 | 0.055 | 1.38 | 0.96–1.99 | 0.082 |
Haematological malignancy | 25 (93%) | 56 (85%) | 2.23 | 0.46–10.94 | 0.322 | |||
AlloBMT | 9 (33%) | 15 (23%) | 1.70 | 0.63–4.56 | 0.291 | |||
Hypoalbuminemia days†, median (IQR) | 22 (11–30) | 16 (10–23) | 1.05 | 1.00–1.10 | 0.058 | 1.04 | 0.98–1.09 | 0.186 |
Mucositis grade, median (IQR) | 0 (0–3) | 0 (0–2) | 1.15 | 0.86–1.54 | 0.336 | |||
Polymicrobial BSI | 7 (26%) | 14 (21%) | 1.30 | 0.46–3.69 | 0.622 | |||
Neutropenia at time of BSI | 20 (74%) | 55 (83%) | 0.57 | 0.20–1.68 | 0.308 | |||
Teicoplanin monotherapy | 14 (52%) | 45 (68%) | 0.54 | 0.22–1.38 | 0.200 | 0.57 | 0.20–1.64 | 0.299 |
ICU 48 h after BSI | 8 (30%) | 5 (8%) | 5.14 | 1.50–17.58 | 0.009 | 4.16 | 1.08–16.00 | 0.038 |